zantac heartburn medicine

---

A Zantac lawsuit has been filed on behalf of those individuals who have developed cancer as a result of Zantac. The makers of Zantac, a popular over-the-counter and prescription heartburn medication, are facing a class-action Zantac lawsuit claiming the drug contains unsafe levels of the cancer-causing substance N-Nitrosodimethylamine (NDMA).

The U.S. Food and Drug Administration (FDA) reported an advisory on September 13, 2019, after discovering the carcinogenic contaminant NDMA in ranitidine, the active ingredient in Zantac, at levels between 3,000 to 26,000 times higher than FDA approved standards.

The FDA acceptable threshold of daily NDMA intake is set at below 100 nanograms. The plaintiffs cited a study that claims that a 150-milligram pill of Zantac contains over 2.5 million nanograms of NDMA. Over the counter Zantac is typically sold in 150-milligram tablets; the recommended dosage to treat peptic ulcer disease for adults is 300 milligrams a night for four to eight weeks.

Plaintiffs allege that Sanofi and Boehringer Ingleham knew the risks of NDMA formation in ranitidine and did not alert the public through the drug’s label or through any other means. Several published studies have shown that ranitidine users have a 400-fold increase of NDMA concentration in their urine. The suit attests that had consumers known the risks, they would not have purchased or consumed ranitidine.

Sold both over-the-counter and as a prescription, Zantac is one of H2 (histamine-2) blockers used to decrease the amount of acid in the stomach. Over-the-counter versions are used to treat common conditions such as heartburn and indigestion. Prescription options of the product are also available to treat and prevent more severe conditions, such as ulcers and gastroesophageal reflux disease.

Zantac manufacturer Sanofi recalled certain batches of the drug in October 2019 amid concerns that they may contain NDMA, a possible carcinogen. The recall included:

• Zantac 150®
• Zantac 150® Cool Mint
• Zantac 75®

Exposure to Zantac and its active ingredient, ranitidine, can lead to an increased risk of developing cancer through NDMA exposure.

Cancers associated with Zantac include:

• Bladder cancer
• Liver cancer
• Esophageal cancer
• Stomach cancer
• Pancreatic cancer

How can the Cohen Hirsch Law Firm help? 

If you or a loved one had been diagnosed with one of the above cancers after frequent and repeated use of Zantac, you may qualify for a claim. Filing a claim can not only help provide you with compensation for medical costs, pain, suffering, and other injuries, but it will also help hold drug manufacturers responsible for the repercussions of selling dangerous products so others can avoid harm in the future. Click here to contact the Cohen Hirsch Law Firm for a free review of your case.